Literature DB >> 29535220

Inhibin Is a Novel Paracrine Factor for Tumor Angiogenesis and Metastasis.

Priyanka Singh1, Laura M Jenkins1, Ben Horst1, Victoria Alers1, Shrikant Pradhan1, Prabhjot Kaur2, Tapasya Srivastava2, Nadine Hempel3, Balázs Győrffy4, Eugenia V Broude5, Nam Y Lee6, Karthikeyan Mythreye7,5.   

Abstract

Inhibin is a heterodimeric TGFβ family ligand that is expressed in many cancers and is a selective biomarker for ovarian cancers; however, its tumor-specific functions remain unknown. Here, we demonstrate that the α subunit of inhibin (INHA), which is critical for the functionality of dimeric inhibin A/B, correlates with microvessel density in human ovarian tissues and is predictive of poor clinical outcomes in multiple cancers. We demonstrate that inhibin-regulated angiogenesis is necessary for metastasis. Although inhibin had no direct impact on tumor cell signaling, both tumor cell-derived and recombinant inhibin elicit a strong paracrine response from endothelial cells by triggering SMAD1/5 activation and angiogenesis in vitro and in vivo Inhibin-induced angiogenesis was abrogated via anti-inhibin α antibodies. The endothelial-specific TGFβ receptor complex comprising ALK1 and endoglin was a crucial mediator of inhibin signaling, offering a molecular mechanism for inhibin-mediated angiogenesis. These results are the first to define a role for inhibin in tumor metastasis and vascularization and offer an antibody-based approach for targeting inhibin therapeutically.Significance: Inhibin is a predictor of poor patient survival in multiple cancers and is a potential target for antiangiogenic therapies. Cancer Res; 78(11); 2978-89. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29535220      PMCID: PMC6510404          DOI: 10.1158/0008-5472.CAN-17-2316

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Inhibin A and B as markers of menopause: a five-year prospective longitudinal study of hormonal changes during the menopausal transition.

Authors:  Inger Overlie; Lars Mørkrid; Anna-Maria Andersson; Niels E Skakkebaek; Mette H Moen; Arne Holte
Journal:  Acta Obstet Gynecol Scand       Date:  2005-03       Impact factor: 3.636

2.  Immunohistochemical staining of hepatocellular carcinoma with monoclonal antibody against inhibin.

Authors:  W G McCluggage; P Maxwell; A Patterson; J M Sloan
Journal:  Histopathology       Date:  1997-06       Impact factor: 5.087

3.  In vivo matrigel migration and angiogenesis assay.

Authors:  Katherine M Malinda
Journal:  Methods Mol Biol       Date:  2009

4.  Betaglycan binds inhibin and can mediate functional antagonism of activin signalling.

Authors:  K A Lewis; P C Gray; A L Blount; L A MacConell; E Wiater; L M Bilezikjian; W Vale
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

5.  Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells.

Authors:  Laurent David; Christine Mallet; Sabine Mazerbourg; Jean-Jacques Feige; Sabine Bailly
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

Review 6.  Mechanisms of transcoelomic metastasis in ovarian cancer.

Authors:  David S P Tan; Roshan Agarwal; Stanley B Kaye
Journal:  Lancet Oncol       Date:  2006-11       Impact factor: 41.316

7.  The TGF-beta family and its composite receptors.

Authors:  J Massagué; L Attisano; J L Wrana
Journal:  Trends Cell Biol       Date:  1994-05       Impact factor: 20.808

8.  Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice.

Authors:  M M Matzuk; M J Finegold; J G Su; A J Hsueh; A Bradley
Journal:  Nature       Date:  1992-11-26       Impact factor: 49.962

9.  Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling.

Authors:  S Kumar; C C Pan; J C Bloodworth; A B Nixon; C Theuer; D G Hoyt; N Y Lee
Journal:  Oncogene       Date:  2013-09-30       Impact factor: 9.867

10.  TGF-β triggers rapid fibrillogenesis via a novel TβRII-dependent fibronectin-trafficking mechanism.

Authors:  Archana Varadaraj; Laura M Jenkins; Priyanka Singh; Anindya Chanda; John Snider; N Y Lee; Ayelet R Amsalem-Zafran; Marcelo Ehrlich; Yoav I Henis; Karthikeyan Mythreye
Journal:  Mol Biol Cell       Date:  2017-03-15       Impact factor: 4.138

View more
  11 in total

1.  Oridonin represses epithelial-mesenchymal transition and angiogenesis of thyroid cancer via downregulating JAK2/STAT3 signaling.

Authors:  Wei Liu; Xindi Wang; Le Wang; Yu Mei; Yanning Yun; Xiaobao Yao; Qian Chen; Jinsong Zhou; Bo Kou
Journal:  Int J Med Sci       Date:  2022-05-27       Impact factor: 3.642

2.  Alterations of 63 hub genes during lingual carcinogenesis in C57BL/6J mice.

Authors:  Hua Liu; Jianjiao Li; Ying Yang; Liu Liu; Lifu Yu; Minsong Tu; Ruihong Yuan; Wanyuan Yue; Qi Luo; Yonghua Ruan; Xiaoming Dai
Journal:  Sci Rep       Date:  2018-08-22       Impact factor: 4.379

3.  Antiangiogenesis effect of timosaponin AIII on HUVECs in vitro and zebrafish embryos in vivo.

Authors:  Zhong-Yan Zhou; Wai-Rong Zhao; Ying Xiao; Xiang-Ming Zhou; Chen Huang; Wen-Ting Shi; Jing Zhang; Qing Ye; Xin-Lin Chen; Jing-Yi Tang
Journal:  Acta Pharmacol Sin       Date:  2019-09-12       Impact factor: 6.150

4.  The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.

Authors:  Wen-Juan Tian; Shan-Shan Liu; Bu-Rong Li
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 5.  TGFβ signaling networks in ovarian cancer progression and plasticity.

Authors:  Asha Kumari; Zainab Shonibare; Mehri Monavarian; Rebecca C Arend; Nam Y Lee; Gareth J Inman; Karthikeyan Mythreye
Journal:  Clin Exp Metastasis       Date:  2021-02-15       Impact factor: 5.150

6.  Antiproliferative, Antiangiogenic, and Antimetastatic Therapy Response by Mangiferin in a Syngeneic Immunocompetent Colorectal Cancer Mouse Model Involves Changes in Mitochondrial Energy Metabolism.

Authors:  Julio César Rodriguez-Gonzalez; Ivones Hernández-Balmaseda; Ken Declerck; Claudina Pérez-Novo; Emilie Logie; Claudia Theys; Patrycja Jakubek; Olga Luisa Quiñones-Maza; Geovanni Dantas-Cassali; Diego Carlos Dos Reis; Guy Van Camp; Miriam Teresa Lopes Paz; Idania Rodeiro-Guerra; René Delgado-Hernández; Wim Vanden Berghe
Journal:  Front Pharmacol       Date:  2021-12-03       Impact factor: 5.810

7.  Exploration of the prognostic signature reflecting tumor microenvironment of lung adenocarcinoma based on immunologically relevant genes.

Authors:  Wei Wu; Liye Jia; Yanan Zhang; Juanjuan Zhao; Yunyun Dong; Yan Qiang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

8.  Development of Tumor Mutation Burden-Related Prognostic Model and Novel Biomarker Identification in Stomach Adenocarcinoma.

Authors:  Min Fu; Yongbiao Huang; Xiaohong Peng; Xiaoyu Li; Na Luo; Wenjun Zhu; Feng Yang; Ziqi Chen; Shengling Ma; Yuanyuan Zhang; Qianxia Li; Guangyuan Hu
Journal:  Front Cell Dev Biol       Date:  2022-03-23

9.  An immature inhibin-α-expressing subpopulation of ovarian clear cell carcinoma cells is related to an unfavorable prognosis.

Authors:  Shinya Kusumoto; Masako Kurashige; Kenji Ohshima; Shinichiro Tahara; Takahiro Matsui; Satoshi Nojima; Satoshi Hattori; Eiichi Morii
Journal:  Cancer Med       Date:  2021-02-20       Impact factor: 4.452

10.  INHBA is a Prognostic Biomarker and Correlated With Immune Cell Infiltration in Cervical Cancer.

Authors:  Kaidi Zhao; Yuexiong Yi; Zhou Ma; Wei Zhang
Journal:  Front Genet       Date:  2022-01-04       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.